Announcement PDF ASX Announcement 22/09/2021 Novel MDMA analogue screening program advanced Highlights: ● A comprehensive preliminary analysis has been completed on the first batch of compounds from Emyria’s exclusively optioned MDMA analogue library, developed at the University of Western Australia (UWA) ● Nuclear-magnetic resonance (NMR) screening and high performance liquid chromatography (HPLC) have confirmed excellent purity and long-term stability at room temperature for all compounds evaluated ● The first batch of compounds are now being prepared for formal neurological screening and comprehensive drug candidate selection and analysis ● An initial set of neurological targets and anti-targets has been identified in consultation with Emyria’s key clinical advisors ● A PhD qualified chemist has been appointed to manage the MDMA analogue screening program, in collaboration with UWA staff Emyria Limited (ASX: EMD) (Emyria or the Company), a data-backed drug development and care delivery company, is pleased to report that the first batch of MDMA analogues exclusively optioned to Emyria - demonstrate excellent purity and stability at room temperature. The purity checks were conducted with nuclear-magnetic resonance (NMR) spectroscopy and further confirmation was completed with high performance liquid chromatography (HPLC). These analyses confirm the high purity and stability of the first 50% of the MDMA analogue library, which is required prior to advancing the screening process. Further testing is now being finalised for the remainder of the library while this first batch of compounds is being prepared for neurological receptor target screening. Neurological target analysis Discussions have also advanced with a major pharmaceutical discovery and screening company, specialising in comprehensive drug candidate selection and an initial set of neurological targets and anti-targets has been selected in collaboration with Emyria’s key advisors (See ASX releases 20 August, 16 September 2021). 1 The planned drug candidate screening panels will provide a comprehensive selection of key in vitro assays and safety models that will help support the prioritisation and progression of the most promising drug candidates within the MDMA library. Screening results can also assist in the consideration of suitable clinical indications for the compounds. A Research Assistant has been hired to assist Emyria in managing the MDMA library. The individual is an PhD qualified chemist who has experience with neurological health research across SE Asia, Australia, UK and the US, including University of Cambridge (schizophrenia project), CHDI Foundation (Cure Huntington’s Disease Initiative) and the National University of Malaysia. Emyria’s Managing Director, Dr. Michael Winlo, said: “We’re delighted to confirm that the first batch of MDMA-analogues evaluated show excellent purity and stability. This is an important first step in our drug development program, which can now progress to comprehensive neurological receptor screening. Emyria’s clinical network and data infrastructure is uniquely positioned and committed to advancing MDMA-assisted therapy in Australia, and MDMA drug development globally, to help treat a variety of major psychiatric and neurological conditions.” Emyria’s MDMA focus In addition to Emyria’s MDMA-assisted psychotherapy clinical program (EMDMA-001), Emyria recently secured exclusive rights to a library of more than 100 novel MDMA analogues from UWA, creating a unique drug-discovery pipeline. (See ASX announcements 05 May, 29 June and 05 August 2021) The library of MDMA compounds has been developed by the highly regarded research group of medicinal chemist, Dr. Matt Piggott, who has been working with MDMA analogues, and exploring their therapeutic potential, for more than 10 years. Emyria is currently screening and expanding the existing library in order to identify families of patentable compounds with the greatest promise as new psychedelic-assisted therapies and treatments for other neurological disorders. Emyria is leading a global patent strategy, already underway, as well as the further clinical development and commercialisation of this underexplored research space Emyria’s MDMA analogue development program has the potential to result in the registration and commercialisation of multiple, novel, CNS-active compounds to help treat patients with major unmet needs. The company will provide further updates as the program advances. This announcement has been approved and authorised for release by the Managing Director of Emyria Limited. 2 For further information: Dr. Michael Winlo Managing Director 1300 436 363 mwinlo@emyria.com Lexi O’Halloran Media/Investor Relations + 61 (0) 404 577 076 lexi@janemorganmanagement.com.au Andrew Williams Media Relations +61 (0) 412 614 125 andreww@profilemedia.com.au About Emyria (www.emyria.com) Emyria Limited is a data-backed clinical drug development and care delivery company. Emyria’s Treatments target large unmet needs and are focused on obtaining approval (“registration”) with major global regulators. Emyria’s treatment development programs are informed by insights generated from extensive analysis of Emyria Data - deep, ethically-sourced clinical evidence that is gathered with patients across Emyria’s independent clinical services (Emerald Clinics - www.emeraldclinics.com.au) Emyria Data provides deep treatment insights and is therefore a source of unique IP, strategically designed drug development and personalised care programs. Cautionary Note on Forward-Looking Statements Any statements in this press release about future expectations, plans and prospects for the Company, the company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company’s ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company’s ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof. 3